Metsystem is developing a personalized medicine platform that utilizes a decision support tool to predict cancer metastasis and guide oncologists in selecting the most effective therapies for patients with solid tumors. This approach addresses tumor heterogeneity, enabling earlier intervention and improved patient outcomes through targeted drug screening and risk assessment.
Funding
$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Solid tumors exhibit significant heterogeneity, both between patients and within individual tumors, making it difficult for oncologists to predict metastasis and select the most effective therapies. Current methods often fail to account for this variability, leading to suboptimal treatment decisions and poorer patient outcomes.
Solution
Metsystem is developing METscreen, a personalized medicine platform that utilizes patient-derived organoids and advanced drug screens to predict cancer metastasis and guide oncologists in selecting effective therapies for patients with solid tumors. The platform addresses tumor heterogeneity by creating a functional assay that accounts for intratumor heterogeneity, providing doctors with actionable insights tailored to each unique case. By bridging cutting-edge science with clinical application, METscreen empowers doctors to make precise, informed treatment decisions based on the cancer’s actual response. The platform aims to predict if and where cancer will spread and identify the most effective treatment for each patient.
Target Audience
The primary users are oncologists and medical professionals treating patients with solid tumors, as well as researchers in personalized cancer medicine.
Features
- Metastasis-targeting technologies to predict cancer spread
- Patient-derived organoids to model individual tumor characteristics
- Advanced drug screens to identify effective treatments
- Functional assay that accounts for intratumor heterogeneity
- Actionable insights tailored to each unique case